All Photos(1)




Pharmaceutical Secondary Standard; Certified Reference Material

4-Methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,9-triene-9-carboxamide, 3-Methyl-4-oxo-8-imidazolo[5,1-d][1,2,3,5]tetrazinecarboxamide, NSC 362856, 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 8-Carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one, Temozolomide
Empirical Formula (Hill Notation):
CAS Number:
Molecular Weight:
MDL number:
PubChem Substance ID:

Quality Level


certified reference material
pharmaceutical secondary standard


current certificate can be downloaded


pkg of 1 g


HPLC: suitable
gas chromatography (GC): suitable


pharmaceutical (small molecule)



pharmacopeia traceability

traceable to USP 1643543

storage temp.


SMILES string




InChI key


Looking for similar products? Visit Product Comparison Guide

General description

Certified pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to pharmacopeia primary standards.
Temozolomide is an alkylating agent of the imidazotetrazine group. It is a chemotherapy drug, used in the treatment of anaplastic astrocytoma, glioblastoma multiforme and malignant metastatic melanoma, which works by arresting cancer cell growth.


These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
Temozolomide may be used as a pharmaceutical reference standard for the determination of the analyte in drug dosage forms by reverse phase liquid chromatography and UV spectrophotometry.

Analysis Note

These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.

Other Notes

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.


To see an example of a Certificate of Analysis for this material enter LRAA2745 in the slot below. This is an example certificate only and may not be the lot that you receive.


Exclamation markHealth hazard

Signal Word


Hazard Classifications

Acute Tox. 4 Oral - Carc. 1B - Eye Irrit. 2 - Muta. 1B - Repr. 1B - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

6.1D - Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects



Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis

Certificate of Origin

Development and Validation of Simultaneous Detrmination of Anastrozole and Temozolomide in Pharmaceutical Dosage Forms.
Daphal VN, et al.
International Journal of Theoretical & Applied Sciences, 4(2), 48-55 (2012)
Design of experiment based validated stability indicating RP-HPLC method of temozolomide in bulk and pharmaceutical dosage forms.
Khan A, et al.
Beni-Suef University Journal of Basic and Applied Sciences, 5(4), 402-408 (2016)
Development and validation of UV method of temozolomide in bulk and capsule formulation.
Razak AA, et al.
International Journal of Pharmaceutical Sciences and Research, 4(4), 1419-1423 (2013)
Yun-Yu Chen et al.
Translational oncology, 14(1), 100897-100897 (2020-10-18)
Zinc(II)-dipicolylamine (Zn-DPA) has been shown to specifically identify and bind to phosphatidylserine (PS), which exists in bulk in the tumor microenvironment. BPRDP056, a Zn-DPA-SN38 conjugate was designed to provide PS-targeted drug delivery of a cytotoxic SN38 to the tumor microenvironment
Hee-Yeon Cho et al.
Molecular cancer therapeutics, 13(8), 2004-2017 (2014-07-06)
Patients with glioblastoma multiforme (GBM), a malignant primary brain tumor, inevitably develop resistance to standard-of-care chemotherapy, temozolomide. This study explores the effects of the novel agent NEO212, a conjugate of temozolomide to perillyl alcohol, on temozolomide-resistant gliomas. NEO212 was tested

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service